PMID- 29217283 OWN - NLM STAT- MEDLINE DCOM- 20190117 LR - 20210109 IS - 1873-7064 (Electronic) IS - 0028-3908 (Print) IS - 0028-3908 (Linking) VI - 136 IP - Pt B DP - 2018 Jul 1 TI - Insulin-mediated synaptic plasticity in the CNS: Anatomical, functional and temporal contexts. PG - 182-191 LID - S0028-3908(17)30590-7 [pii] LID - 10.1016/j.neuropharm.2017.12.001 [doi] AB - For decades the brain was erroneously considered an insulin insensitive organ. Although gaps in our knowledge base remain, conceptual frameworks are starting to emerge to provide insight into the mechanisms through which insulin facilitates critical brain functions like metabolism, cognition, and motivated behaviors. These diverse physiological and behavioral activities highlight the region-specific activities of insulin in the CNS; that is, there is an anatomical context to the activities of insulin in the CNS. Similarly, there is also a temporal context to the activities of insulin in the CNS. Indeed, brain insulin receptor activity can be conceptualized as a continuum in which insulin promotes neuroplasticity from development into adulthood where it is an integral part of healthy brain function. Unfortunately, brain insulin resistance likely contributes to neuroplasticity deficits in obesity and type 2 diabetes mellitus (T2DM). This neuroplasticity continuum can be conceptualized by the mechanisms through which insulin promotes cognitive function through its actions in brain regions like the hippocampus, as well as the ability of insulin to modulate motivated behaviors through actions in brain regions like the nucleus accumbens and the ventral tegmental area. Thus, the goals of this review are to highlight these anatomical, temporal, and functional contexts of insulin activity in these brain regions, and to identify potentially critical time points along this continuum where the transition from enhancement of neuroplasticity to impairment may take place. This article is part of the Special Issue entitled 'Metabolic Impairment as Risk Factors for Neurodegenerative Disorders.' CI - Copyright (c) 2017 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Ferrario, Carrie R AU - Ferrario CR AD - Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. Electronic address: Ferrario@umich.edu. FAU - Reagan, Lawrence P AU - Reagan LP AD - Department of Pharmacology, Physiology and Neuroscience, University of South Carolina School of Medicine, Columbia, SC 29208, USA; W.J.B. Dorn VA Medical Center, Columbia, SC 29208, USA. LA - eng GR - I01 BX001804/BX/BLRD VA/United States GR - I01 BX002664/BX/BLRD VA/United States GR - R01 DK106188/DK/NIDDK NIH HHS/United States GR - R01 DK115526/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Review DEP - 20171205 PL - England TA - Neuropharmacology JT - Neuropharmacology JID - 0236217 RN - 0 (Insulin) SB - IM MH - Animals MH - Central Nervous System/anatomy & histology/*metabolism MH - Humans MH - Insulin/*metabolism MH - Neuronal Plasticity/*physiology PMC - PMC5988909 MID - NIHMS927597 OTO - NOTNLM OT - Cognition OT - Glutamate OT - Hippocampus OT - Motivation OT - Nucleus accumbens OT - Ventral tegmental area COIS- The authors have no conflicts of interest to declare. EDAT- 2017/12/09 06:00 MHDA- 2019/01/18 06:00 PMCR- 2019/07/01 CRDT- 2017/12/09 06:00 PHST- 2017/10/16 00:00 [received] PHST- 2017/12/01 00:00 [revised] PHST- 2017/12/03 00:00 [accepted] PHST- 2017/12/09 06:00 [pubmed] PHST- 2019/01/18 06:00 [medline] PHST- 2017/12/09 06:00 [entrez] PHST- 2019/07/01 00:00 [pmc-release] AID - S0028-3908(17)30590-7 [pii] AID - 10.1016/j.neuropharm.2017.12.001 [doi] PST - ppublish SO - Neuropharmacology. 2018 Jul 1;136(Pt B):182-191. doi: 10.1016/j.neuropharm.2017.12.001. Epub 2017 Dec 5.